1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P07714, 2011-005186-20, NCT01580228
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000655386, DFCI-09152, 09-152, 8296, NCT01026324
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-11120, OSU11120, 9031, NCT01515176
|
|
4.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-11-144, 11-144, 8484, NCT01434316
|
|
5.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00950, R01CA152228, 2012-0229, NCT01624441
|
|
6.
|
Phase: Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P07974, 2012-001437-14, MK-7965-011, NCT01650727
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UCSF CC# 12951, NCT01676753
|